➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,916,941

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,916,941 protect, and when does it expire?

Patent 6,916,941 protects LEXAPRO and is included in one NDA.

Protection for LEXAPRO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-six patent family members in thirty-eight countries.

Summary for Patent: 6,916,941
Title: Crystalline composition containing escitalopram
Abstract:Crystalline particles of escitalopram oxalate with a particle size of at least 40 .mu.m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
Inventor(s): Christensen; Troels Volsgaard (Holb.ae butted.k, DK), Liljegren; Ken (V.ae butted.rl.o slashed.se, DK), Elema; Michiel Onne (K.o slashed.bnhavn .O slashed., DK), Andresen; Lene (R.o slashed.dovre, DK), Mahashabde; Shashank (Kendall Park, NJ), Assenza; Sebastian P. (Fort Salonga, NY)
Assignee: H. Lundbeck A/S (Valby-Copenhagen, DK)
Application Number:10/403,453
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Dosage form; Composition;

Drugs Protected by US Patent 6,916,941

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Allergan LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,916,941

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
DenmarkPA 2001 01164Jul 31, 2001

International Family Members for US Patent 6,916,941

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034898   Start Trial
Austria 286730   Start Trial
Austria 352546   Start Trial
Australia 2002355624   Start Trial
Bulgaria 108571   Start Trial
Brazil 0206164   Start Trial
Canada 2451915   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.